WO2025057088 - RNA COMPOSITIONS FOR DELIVERY OF INCRETIN AGENTS
National phase entry:
Publication Number
WO/2025/057088
Publication Date
20.03.2025
International Application No.
PCT/IB2024/058845
International Filing Date
11.09.2024
Title **
[English]
RNA COMPOSITIONS FOR DELIVERY OF INCRETIN AGENTS
[French]
COMPOSITIONS D'ARN POUR ADMINISTRATION D'AGENTS D'INCRÉTINE
Applicants **
BIONTECH SE
RESANO GMBH
MICULKA, Christian
Inventors
DULBERGER, Charles Lefco
YEGANEH, Fahimeh
REINSCH, Christian
KUHN, Andreas
FISCHER, Roman
Priority Data
PCT/IB2023/059007
11.09.2023
IB
63/662,890
21.06.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 9766 | |
| EPO | Filing, Examination, Granting | 254303 | |
| Japan | Filing, Examination, Granting | 5476 | |
| South Korea | Filing, Examination, Granting | 14568 | |
| USA | Filing, Examination, Granting | 51790 |
Total:
335,903
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of incretin agents and related technologies (e.g., components thereof and/or methods relating thereto). Among other things, the present disclosure provides treatment methods using polyribonucleotides encoding incretin agents for various diseases.[French]
La présente divulgation concerne des compositions (par exemple, des compositions pharmaceutiques) pour l'administration d'agents d'incrétine et des technologies associées (par exemple, des constituants de ceux-ci et/ou des méthodes associées). Entre autres, la présente divulgation concerne des méthodes de traitement utilisant des polyribonucléotides codant des agents d'incrétine contre diverses maladies.